FDA Clears First Fixed-Dose Combination Treatment for Gout

Share this post

Duzallo combines lesinurad and allopurinol and is indicated for gout-associated hyperuricemia in patients for whom target serum uric acid levels are not achieved with allopurinol alone.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Share this post

Be the first to comment

Leave a Reply